vs
Side-by-side financial comparison of Mind Medicine (MindMed) Inc. (DFTX) and SOCIETY PASS INCORPORATED. (SOPA). Click either name above to swap in a different company.
SOCIETY PASS INCORPORATED. is the larger business by last-quarter revenue ($1.4M vs $906.0K, roughly 1.5× Mind Medicine (MindMed) Inc.). SOCIETY PASS INCORPORATED. runs the higher net margin — -370.8% vs -2634.0%, a 2263.2% gap on every dollar of revenue. On growth, Mind Medicine (MindMed) Inc. posted the faster year-over-year revenue change (-16.1% vs -17.6%).
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
The Wilderness Society is an Australian, community-based, not-for-profit non-governmental environmental advocacy organisation.
DFTX vs SOPA — Head-to-Head
Income Statement — Q4 FY2023 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $906.0K | $1.4M |
| Net Profit | $-23.9M | $-5.1M |
| Gross Margin | — | 64.3% |
| Operating Margin | -2450.8% | -379.9% |
| Net Margin | -2634.0% | -370.8% |
| Revenue YoY | -16.1% | -17.6% |
| Net Profit YoY | -386.7% | -271.5% |
| EPS (diluted) | $-0.58 | $-0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $1.4M | ||
| Q2 25 | — | $2.5M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $1.8M | ||
| Q4 23 | $906.0K | $1.7M |
| Q3 25 | — | $-5.1M | ||
| Q2 25 | — | $479.0K | ||
| Q1 25 | — | $-1.8M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.9M | ||
| Q1 24 | — | $-2.8M | ||
| Q4 23 | $-23.9M | $-5.7M |
| Q3 25 | — | 64.3% | ||
| Q2 25 | — | 56.5% | ||
| Q1 25 | — | 31.6% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | — | 21.8% | ||
| Q2 24 | — | 27.1% | ||
| Q1 24 | — | 26.7% | ||
| Q4 23 | — | 36.8% |
| Q3 25 | — | -379.9% | ||
| Q2 25 | — | -6.1% | ||
| Q1 25 | — | -126.6% | ||
| Q4 24 | — | -165.6% | ||
| Q3 24 | — | -70.1% | ||
| Q2 24 | — | -126.0% | ||
| Q1 24 | — | -156.6% | ||
| Q4 23 | -2450.8% | -283.1% |
| Q3 25 | — | -370.8% | ||
| Q2 25 | — | 19.1% | ||
| Q1 25 | — | -124.9% | ||
| Q4 24 | — | -217.5% | ||
| Q3 24 | — | -82.2% | ||
| Q2 24 | — | -113.3% | ||
| Q1 24 | — | -153.8% | ||
| Q4 23 | -2634.0% | -323.7% |
| Q3 25 | — | $-0.89 | ||
| Q2 25 | — | $0.10 | ||
| Q1 25 | — | $-0.44 | ||
| Q4 24 | — | $-1.03 | ||
| Q3 24 | — | $-0.48 | ||
| Q2 24 | — | $-0.73 | ||
| Q1 24 | — | $-1.21 | ||
| Q4 23 | $-0.58 | $-2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $99.7M | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $78.1M | $13.9M |
| Total Assets | $124.5M | $32.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $6.6M | ||
| Q2 25 | — | $8.2M | ||
| Q1 25 | — | $7.1M | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | — | $4.2M | ||
| Q2 24 | — | $833.9K | ||
| Q1 24 | — | $1.6M | ||
| Q4 23 | $99.7M | $3.6M |
| Q3 25 | — | $13.9M | ||
| Q2 25 | — | $2.4M | ||
| Q1 25 | — | $-663.0K | ||
| Q4 24 | — | $-2.1M | ||
| Q3 24 | — | $862.6K | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | $3.5M | ||
| Q4 23 | $78.1M | $5.3M |
| Q3 25 | — | $32.9M | ||
| Q2 25 | — | $29.2M | ||
| Q1 25 | — | $22.9M | ||
| Q4 24 | — | $21.3M | ||
| Q3 24 | — | $17.0M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $13.3M | ||
| Q4 23 | $124.5M | $16.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-20.6M | $-16.7M |
| Free Cash FlowOCF − Capex | — | $-16.7M |
| FCF MarginFCF / Revenue | — | -1211.0% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-16.7M | ||
| Q2 25 | — | $-1.8M | ||
| Q1 25 | — | $-4.0M | ||
| Q4 24 | — | $3.7M | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $-864.6K | ||
| Q1 24 | — | $-2.4M | ||
| Q4 23 | $-20.6M | $-4.1M |
| Q3 25 | — | $-16.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $-4.1M |
| Q3 25 | — | -1211.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | -235.8% |
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | 1.9% |
| Q3 25 | — | — | ||
| Q2 25 | — | -3.70× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
